# Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS

> **NCT00844428** · PHASE2 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Atypical Hemolytic Uremic Syndrome

## Interventions

- **DRUG:** eculizumab

## Key facts

- **NCT ID:** NCT00844428
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-10
- **Final completion:** 2013-12
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2015-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00844428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00844428, "Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00844428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*